Development of 2-thioxoquinazoline-4-one derivatives as dual and selective inhibitors of dynamin-related protein 1 (Drp1) and puromycin-sensitive aminopeptidase (PSA).
Akiyoshi Numadate, Yusuke Mita, Yotaro Matsumoto, Shinya Fujii, Yuichi Hashimoto
文献索引:Chem. Pharm. Bull. 62(10) , 979-88, (2014)
全文:HTML全文
摘要
An established inhibitor of dynamin-related protein 1 (Drp1), 3-(2,4-dichloro-5-methoxyphenyl)-2-thioxoquinazoline-4-one (mdivi-1), was recently reported also to show potent puromycin-sensitive aminopeptidase (PSA)-inhibitory activity. Herein, we report structural development of mdivi-1 derivatives and structure-activity relationship (SAR) analysis of the synthesized compounds, as well as the structurally related PSA-specific inhibitor 3-(2,6-diethylphenyl)quinazoline-2,4-dione (PAQ-22), with the aim of identifying key structural features for inhibitory activity in order to develop selective inhibitors of Drp1, which is a potential target for treatment of Huntington's disease. Among the synthesized compounds, 3-(4-chloro-3-methoxyphenyl)-2-thioxoquinazoline-4-one (10g) exhibited more potent Drp1-inhibitory activity than mdivi-1 with high selectivity for Drp1 over PSA.
相关化合物
相关文献:
2014-08-01
[Mol. Plant 7(8) , 1365-83, (2014)]
2014-07-01
[Nucleic Acids Res. 42(12) , 8106-14, (2014)]
2015-01-01
[J. Invest. Dermatol. 135(1) , 102-9, (2014)]
2015-04-01
[J. Autoimmun. 58 , 78-89, (2015)]
2014-06-01
[Pharm. Res. 31(6) , 1512-24, (2014)]